Tags : Opdivo

BMS’ Opdivo (nivolumab) Receives EC’s Approval as 2L Treatment for

Tuba Khan November 25, 2020

Shots: The approval is based on P-lll ATTRACTION-3 study involve the assessment of Opdivo vs CT (docetaxel or paclitaxel) for patients with esophageal cancer refractory/ intolerant to 1L combination therapy with fluoropyrimidine- and Pt.-based drugs Results: reduction in risk of death (23%); m-OS (10.9 vs 8.4 mos.); @12 & 18-mos. OS rates (47% & 31% […]Read More

Clinical Trials

BMS Report Results of Opdivo (nivolumab) + CT in P-III

Tuba Khan October 8, 2020

Shots: The P-III CheckMate-816 study involves assessing of Opdivo (360mg) + CT (q3w for 3 doses) vs CT (q3w for 3 doses), followed by surgery as a neoadjuvant treatment in 358 patients with resectable NSCLC The study met its 1EPs of improved pathologic complete response. The positive results mark the first time an immune checkpoint […]Read More

Clinical Trials

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274

Tuba Khan September 25, 2020

Shots: The P-III CheckMate -274 study involves assessing of Opdivo vs PBO in 709 patients in a ratio (1:1) with muscle-invasive urothelial cancer at a high risk of recurrence after radical surgery for up to 1yr. The study met its 1EPs of DFS in both all randomized patients and in patients whose tumor cells express […]Read More

Biosimilars

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

Tuba Khan September 1, 2020

Shots: The company discloses two additional biosimilars in active development referencing Opdivo (nivolumab) and Keytruda (pembrolizumab). The biosimilars are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and Serum Institute of India The disclosure demonstrates NeuClone’s ability to develop multiple biosimilars simultaneously through its NeuMAX platform Additionally, NeuClone and Serum […]Read More

Regulatory

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) + CT Receive Health

Tuba Khan August 12, 2020

Shots: The approval is based on P-III CheckMate -9LA study assessing Opdivo + Yervoy combined with two cycles of platinum-doublet CT vs CT (four cycles followed by optional pemetrexed maintenance therapy if eligible) as a 1L treatment in patients with metastatic/ recurrent NSCLC regardless of PD-L1 expression and histology The study met its 1EPs & […]Read More

Top 20

Top 20 Prescription Drugs Based on 2019 Revenue

Vartika Singh July 17, 2020

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More

Regulatory

BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval for Advanced

Tuba Khan June 11, 2020

Shots: The US FDA’s approval is based on P-III ATTRACTION-3 study assessing Opdivo (240mg by IV infusion over 30min, q2w) vs taxane CT (docetaxel/paclitaxel) in patients with unresectable advanced, recurrent or ESCC, refractory/ intolerant to at least one prior fluoropyrimidine & platinum-based CT Opdivo is the first approved immunotherapy in this setting regardless of tumor […]Read More

Pharma

BMS Signs a Clinical Trial Collaboration with NeoImmune to Evaluate

Vartika Singh April 10, 2020

Shots: NeoImmuneTech to sponsor the trial and BMS will supply Opdivo (nivolumab) for the use in the trial. Additionally, under Master Clinical Trial Collaboration Agreement, the first study will be focusing on gastric/GEJ/EAC cancers and the companies can evaluate additional combination trials in the future The goal of the collaboration is to evaluate preliminary anti-tumor […]Read More

Regulatory

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA’s

Tuba Khan March 11, 2020

Shots: The approval is based on P-I/II CheckMate -040 study assessing Opdivo (1 mg/kg, IV) + Yervoy (3 mg/kg, IV) q3w for four doses, followed by Opdivo (240mg, q2w) in 49 patients with HCC prior treated with sorafenib The P-I/II CheckMate -040 study results: @28mos. follow-up, 33% of patients respond to combination therapy; CR (8%); […]Read More

Regulatory

BMS Reports the US FDA Acceptance of sBLA for Opdivo

Tuba Khan January 16, 2020

Shots: The US FDA has accepted sBLA for the dual regimen as 1L treatment for metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations and has granted the PR status to the therapy The application is based on part 1 of P-III CheckMate -227 study results assessing Opdivo + Yervoy vs platinum-doublet […]Read More

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

Boehringer Ingelheim Collaborates with Cure Genetics to Develop Next-Generation Liver-Targeted Gene Therapy

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Henlius’ HLX15 (biosimilar, daratumumab) Receives IND Approval for Multiple Myeloma in China

Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

The US Government to Purchase Additional Doses of Regeneron’s Casirivimab and Imdevimab to Combat COVID-19

Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma

Genmab’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receives the US FDA’s Approval for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021

Tags : Opdivo

BMS’ Opdivo (nivolumab) Receives EC’s Approval as 2L Treatment for

BMS Report Results of Opdivo (nivolumab) + CT in P-III

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) + CT Receive Health

Top 20 Prescription Drugs Based on 2019 Revenue

BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval for Advanced

BMS Signs a Clinical Trial Collaboration with NeoImmune to Evaluate

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receive the US FDA’s

BMS Reports the US FDA Acceptance of sBLA for Opdivo

Latest Posts

ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

Philips to Acquire Capsule Technologies for ~$635M

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Tags : Opdivo

Latest Posts

Categories

Related Topics